Ben Battistone

Ben Battistone

Auto-generated profile, based on publicly available information

Ben Battistone

University of Utah 1 Division of Microbiology and Immunology, Department of Pathology Salt Lake City, Utah

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Cell Reports
Verified
Journal Article
Open access
AVAria Vaishnavi
Aria Vaishnavi
MSMichael T. Scherzer
Michael T. Scherzer
CKConan G. Kinsey
Conan G. Kinsey
GPGennie Parkman
Gennie Parkman
ATAmanda Truong
Amanda Truong
MMMartin McMahon
Martin McMahon
NTRK1 gene fusions are actionable drivers of numerous human malignancies. Here, we show that expression of the TPR-NTRK1 fusion kinase in immortalized mouse pancreatic ductal epithelial (IMPE) (pancreas) or mouse lung epithelial (MLE-12) cells is sufficient to promote rapidly growing tumors in mice. Both tumor models are exquisitely sensitive to targeted inhibition with entrectinib, a tropomyosin-related kinase A (TRKA) inhibitor. Initial regression of NTRK1-driven tumors is driven by induced expression of BIM, such that BIM silencing leads to a diminished response to entrectinib in vivo. However, the emergence of drug-resistant disease limits the long-term durability of responses. Based on the reactivation of RAF>MEK>ERK signaling observed in entrectinib-treated tumors, we show that the combination of entrectinib plus the MEK1/2 inhibitor cobimetinib dramatically forestalls the onset of drug resistance in vivo. Collectively, these data provide a mechanistic rationale for rapid clinical deployment of combined inhibition of TRKA plus MEK1/2 in NTRK1-driven cancers.

14 May 2020 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
MFMona Foth
Mona Foth
GPGennie Parkman
Gennie Parkman
BBBenjamin Battistone
Benjamin Battistone
MMMartin McMahon
Martin McMahon

1 February 2026 in Cancer Research Communications
Verified
Journal Article
Open access
MNMorgan C. Nelson
Morgan C. Nelson
LOLiam C. O’MAlley
Liam C. O’MAlley
SLSoh-Hyun Lee
Soh-Hyun Lee
KBKaylyn M. Bauer
Kaylyn M. Bauer
AGArevik Ghazaryan
Arevik Ghazaryan
RORyan M. O'Connell
Ryan M. O'Connell
The miRNA microRNA-146a (miR-146a) regulates several aspects of chronic inflammation, including the hepatocellular carcinoma (HCC) risk factor, steatohepatitis. In this study, we find that the loss of miR-146a leads to a significantly increased tumor burden over a 9-month time frame in a mouse model of HCC. Notably, this miR-146a−/− phenotype is most pronounced in females, who are typically not sensitive to this model. Mechanistically, we identified increases in dysfunctional CD8+ T cells that express high levels of CCL5 and resemble age-associated T (Taa) cells, as well as elevated levels of myeloid cells with a myeloid-derived suppressor cell (MDSC) phenotype, a class of myeloid cells that suppresses tumor immunity. Deletion of Ccl5 from miR-146a–deficient mice returned tumor growth and the aberrant myeloid cell populations to wild-type levels. Surprisingly, deletion of Ccl5 did not rescue the gross metabolic phenotype observed in miR-146a−/− mice subjected to HCC induction, indicating that miR-146a plays an independent role in regulating HCC and metabolic disease. Taken together, this work reveals a critical host-protective role for miR-146a in HCC that is mechanistically dependent on CCL5 and wherein tumor burden correlates with two suppressive immune populations, providing an impetus for targeting these pathways to combat HCC. Furthermore, the correlations with tumor burden and Taa cells suggest that aging may increase HCC risk through the accumulation of CCL5-expressing Taa cells. Significance: The findings in this study highlight the potential of a miRNA-based therapy in the treatment of, and as a biomarker for, liver cancer, something especially promising given the liver’s avid uptake of RNA. Additionally, this work reveals possible causal roles in liver cancer for two unique immune cell types that are prevented by miR-146a.

20 February 2026
Verified
Other
Open access
MNMorgan C. Nelson
Morgan C. Nelson
LOLiam C. O’MAlley
Liam C. O’MAlley
SLSoh-Hyun Lee
Soh-Hyun Lee
KBKaylyn M. Bauer
Kaylyn M. Bauer
AGArevik Ghazaryan
Arevik Ghazaryan
RORyan M. O'Connell
Ryan M. O'Connell
QPCR primers used in experiments

20 February 2026
Verified
Other
Open access
MNMorgan C. Nelson
Morgan C. Nelson
LOLiam C. O’MAlley
Liam C. O’MAlley
SLSoh-Hyun Lee
Soh-Hyun Lee
KBKaylyn M. Bauer
Kaylyn M. Bauer
AGArevik Ghazaryan
Arevik Ghazaryan
RORyan M. O'Connell
Ryan M. O'Connell
Examples of lesions in DEN-treated WT and miR-146a−/− female mouse livers. A and B, Focus of cytologic alteration (FCA). At 10× (A), the lesion appears as a small (less than 2 mm) zone of more darkly staining hepatocytes. At 40×, nonlesional hepatocytes at the periphery of the lesion (top) appear larger than cells within the FCA (bottom). C and D, Hepatocellular adenoma (HCA). At 4× (C), the tumor can be seen to distort the liver capsule (arrow), and no normal portal tracts are seen within the lesion. At 20× (D), nonlesional hepatocytes at the periphery of the lesion (top left) are compressed. E and F, HCC. At 4× (E), the tumor shows a zone of necrosis (arrow). The lesion lacks normal portal tracts, and the surrounding nonlesional hepatocytes are compressed. Nuclear enlargement, nuclear contour irregularities, increased nuclear-to-cytoplasmic ratios, and architectural disarray are seen at 40× (F). H&E stains. Scale bars are 40 μm (A, B, D, and F) or 400 μm (C and E). G, Microscopic tumors were counted from one right lobe of each liver. H, Tumor severity and size. 0 = no tumor; 1 = FCA ≤1 mm; 2 = FCA >1 mm; 3 = HCC or HCA ≤2 mm; 4 = HCC or HCA >2 mm (*Fisher’s exact test separated between HCA/HCC and non-HCA/HCC). Data represent three experiments. The bar chart (G) displays points representing individual mice and error bars representing mean ± SEM. *, P < 0.05; **, P < 0.01.

20 February 2026
Verified
Other
Open access
MNMorgan C. Nelson
Morgan C. Nelson
LOLiam C. O’MAlley
Liam C. O’MAlley
SLSoh-Hyun Lee
Soh-Hyun Lee
KBKaylyn M. Bauer
Kaylyn M. Bauer
AGArevik Ghazaryan
Arevik Ghazaryan
RORyan M. O'Connell
Ryan M. O'Connell
Ccl5 is highly associated with aging miR-146a−/− CD8+ T cells, and its expression is elevated in miR-146a−/− male and female mice. A, scRNA-seq analysis of samples from young and aged (15 months) WT or miR-146a−/− splenocytes from male and female mice using CIPR to annotate cell populations and to localize Ccl5 expression in UMAP plot clusters. B and C, Increased Ccl5 expression in aged miR-146a−/− CD8+ effector T cells from the same mice as A. D, Flow analysis in CD8+ T cells shows increased CCL5 staining in female miR-146a−/− liver. E, qRT-PCR for Ccl5 expression in sorted CD8+ T cells from female WT or miR-146a−/− splenocytes. F–H, qRT-PCR analysis of Ccl5, Gzmk, and Pdcdc1 (PD-1), respectively, in livers from WT or miR-146a−/− DEN-CDHFD–treated female mice. I, Quantification and representative flow plots of age-associated CD8 T cells (Taa cells) in the liver of male and female WT and miR-146a−/− aged, cancer-free mice. J, Surface marker expression profile of Taa cells in male and female WT and miR-146a−/− aged, cancer-free mice relative to an unstained liver sample. Bar charts contain dots representing individual mice, and error bars represent mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. scRNA-seq data have been uploaded to the NCBI Gene Expression Omnibus database (GSE138222).